The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex

被引:202
|
作者
Cheng, KY
Lowe, ED
Sinclair, J
Nigg, EA
Johnson, LN
机构
[1] Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England
[2] Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany
关键词
cell cycle control; Plk1; polo box domain; phospho-peptide recognition; protein structure;
D O I
10.1093/emboj/cdg558
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human polo-like kinase Plk1 localizes to the centrosomes, kinetochores and central spindle structures during mitosis. It plays an essential role in promoting mitosis and cytokinesis through phosphorylation of a number of different substrates. Kinase activity is regulated by a conserved C-terminal domain, termed the polo box domain (PBD), which acts both as an autoinhibitory domain and as a subcellular localization domain. We have determined the crystal structure of Plk1 PBD (residues 367-603) to 2.2 Angstrom resolution and the structure of a phospho-peptide-PBD (residues 345-603) complex to 2.3 Angstrom resolution. The two polo boxes of the PBD exhibit identical folds based on a six-stranded beta-sheet and an alpha-helix, despite only 12% sequence identity. The phospho-peptide binds at a site between the two polo boxes. It makes a short antiparallel beta-sheet connection and critical contacts to residues Trp414, Leu490, His538 and Lys540. Most of these residues had been shown to be important for biological activity through mutational studies. The results provide an explanation for phospho-peptide recognition and create the basis for new functional studies.
引用
收藏
页码:5757 / 5768
页数:12
相关论文
共 46 条
  • [21] MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate
    Abdelfatah, Sara
    Berg, Angela
    Huang, Qi
    Yang, Li Jun
    Hamdoun, Sami
    Klinger, Anette
    Greten, Henry J.
    Fleischer, Edmond
    Berg, Thorsten
    Wong, Vincent K. W.
    Efferth, Thomas
    ACTA PHARMACEUTICA SINICA B, 2019, 9 (05) : 1021 - 1034
  • [22] MCC1019,a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel,potent anticancer candidate
    Sara Abdelfatah
    Angela Berg
    Qi Huang
    Li Jun Yang
    Sami Hamdoun
    Anette Klinger
    Henry J.Greten
    Edmond Fleischer
    Thorsten Berg
    Vincent K.W.Wong
    Thomas Efferth
    Acta Pharmaceutica Sinica B, 2019, 9 (05) : 1021 - 1034
  • [23] Phosphatase-Stable Phosphoamino Acid Mimetics That Enhance Binding Affinities with the Polo-Box Domain of Polo-like Kinase 1
    Hymel, David
    Burke, Terrence R., Jr.
    CHEMMEDCHEM, 2017, 12 (03) : 202 - 206
  • [24] Structural Optimization and Anticancer Activity of Polo-like Kinase 1 (Plk1) Polo-Box Domain (PBD) Inhibitors and Their Prodrugs
    Park, Jung-Eun
    Lee, Hobin
    Oliva, Paola
    Kirsch, Klara
    Kim, Bora
    Ahn, Jong Il
    Alverez, Celeste N.
    Gaikwad, Snehal
    Krausz, Kristopher W.
    O'Connor, Robert
    Rai, Ganesha
    Simeonov, Anton
    Mock, Beverly A.
    Gonzalez, Frank J.
    Lee, Kyung S.
    Jacobson, Kenneth A.
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2023, 6 (03) : 422 - 446
  • [25] Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position
    Qian, Wenjian
    Park, Jung-Eun
    Liu, Fa
    Lee, Kyung S.
    Burke, Terrence R., Jr.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (14) : 3996 - 4003
  • [26] Design, synthesis and evaluation of D-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1
    Li, Zhiyan
    Zhang, Zhenguo
    Chen, Yanhong
    Tang, Shijun
    Lin, Tongyuan
    Huang, Jingfang
    Li, Bo
    Jiang, Cheng
    BIOORGANIC CHEMISTRY, 2019, 85 : 534 - 540
  • [27] Development of a High Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer
    Kim, Tae Gi
    Lee, Ju Hee
    Lee, Mi Young
    Kima, Ka-Ul
    Lee, Jeong Hyun
    Park, Chi Hoon
    Lee, Byung Ho
    Oh, Kwang-Seok
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2017, 40 (09) : 1454 - 1462
  • [28] DITMD-induced mitotic defects and apoptosis in tumor cells by blocking the polo-box domain-dependent functions of polo-like kinase 1
    Kim, Ka-Ul
    Lee, Ju Hee
    Lee, Mi Young
    Chae, Chong Hak
    Lee, Jeong Hyun
    Lee, Byung Ho
    Oh, Kwang-Seok
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 847 : 113 - 122
  • [29] The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation
    Li, Li
    Wang, Xu
    Chen, Jing
    Ding, Hong
    Zhang, Yu
    Hu, Tian-cen
    Hu, Li-hong
    Jiang, Hua-liang
    Shen, Xu
    ACTA PHARMACOLOGICA SINICA, 2009, 30 (10) : 1443 - 1453
  • [30] Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors
    Zhao, Xue Zhi
    Tsuji, Kohei
    Hymel, David
    Burke, Terrence R., Jr.
    MOLECULES, 2019, 24 (08)